IMW 2021 | Treatment-free intervals for patients with myeloma
Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, Birmingham, AL, talks on whether it is possible to give patients with multiple myeloma treatment-free intervals. Dr Costa discusses the role of continuous therapy and comments on its caveats, such as increased risk of secondary malignancies and high costs. Dr Costa also describes the uniform approach of single agent maintenance therapy and developments which can improve the allocation of maintenance therapy to patients, such as measurable residual disease (MRD) monitoring. Dr Costa outlines findings from the IFM/DFCI2009 study (NCT01191060) and the Cassiopeia (NCT02541383) trial and talks on how these trials demonstrate the potential benefits of MRD monitoring in the absence of maintenance therapy. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
